Regulation of tumor angiogenesis by p53-induced degradation of hypoxia- inducible factor 1α

Genes and Development

Volumn 14, Issue 1, 2000, Pages 34-44

  Ravi, Rajani ^a   Mookerjee, Bijoyesh ^a   Bhujwalla, Zaver M ^b   Sutter, Carrie Hayes ^b   Artemov, Dmitri ^b   Zeng, Qinwen ^a   Dillehay, Larry E ^a   Madan, Ashima ^c   Semenza, Gregg L ^b   Bedi, Atul ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer; Hypoxia; Hypoxia inducible factor 1 (HIF 1); p53; Vascular endothelial growth factor (VEGF)

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEASOME; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CARCINOMA CELL; COLON ADENOCARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; CELL DIVISION; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; GENOTYPE; HUMANS; HYDROLYSIS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOKINES; MICE; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; OXYGEN; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA; MUS MUSCULUS;

EID: 0033954247     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. An, W.G., M. Kanekal, M.C. Simon, E. Maltepe, M.V. Blagosklonny, and L.M. Neckers. 1998. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 392: 405-408.
2. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. Mdm-2 expression is induced by wild type p53 activity. EMBO J. 12: 461-468.
3. Bergers, G., K. Javaherian, K.N. Lo, J. Folkman, and D. Hanahan. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812.
4. Blagosklonny, M.V., W.G. An, L.Y. Romanova, J. Trepel, T. Fojo, and L. Neckers. 1998. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273: 11995-11998.
5. Boehm, T., J. Folkman, T. Browder, and M.S. O'Reilly. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407.
6. Bouvet, M., L.M. Ellis, M. Nishizaki, T. Fujiwara, W. Liu, C.D. Bucana, B. Fang, J.J. Lee, and J.A. Roth. 1998. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58: 2288-2292.
7. Brown, J.M. and A.J. Giaccia. 1998. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 58: 1408-1416.
8. Brown, L.F., M. Detmar, K. Claffey, J.A. Nagy, D. Feng, A.M. Dvorak, and H.F. Dvorak. 1996. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. In Control of angiogenesis (ed. I.D. Goldberg and E. Rosen). Birkhauser Verlag, Berlin, Germany.
9. Bunz, F., A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J.P. Brown, J.M. Sedivy, K.W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
10. Carmeliet, P., Y. Dor, J.M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwellet al. 1998. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490.
11. Chowdary, D.R., J.J. Dermody, K.K. Jha, and H.L. Ozer. 1994. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol. 14: 1997-2003.
12. Dameron, K.M., O.V. Volpert, M.A. Tainsky, and N. Bouck. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584.
13. Dang, C.V. and G.L. Semenza. 1999. Oncogenic alterations of metabolism. Trends Biochem. Sci. 24: 68-72.
14. Ferrara, N. 1993. Vascular endothelial growth factor. Trends Cardiovasc. Med. 3: 244-250.
15. Folkman, J. 1997. Tumor angiogenesis. In Cancer Medicine (ed. J.F. Holland, R.C. Bast, Jr., D.L. Morton, E. Frei III, D.W. Kufe, and R.R. Weichselbaum), pp 181-204. Williams & Wilkins, Baltimore, MD.
16. Folkman, J., K. Watson, D. Ingber, and D. Hanahan. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
17. Fontanini, G., L. Boldrini, S. Vignati, S. Chine, F. Basolo, V. Silvestri, M. Lucchi, A. Mussi, C.A. Angeletti, and G. Bevilacqua. 1998. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur. J. Cancer. 34: 718-723.
18. Forsythe, J.A., B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, and G.L. Semenza. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor1. Mol. Cell. Biol. 16: 4604-4613.
19. Giaccia, A.J. and M.B. Kastan. 1998. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes & Dev. 12: 2973-2983.
20. Gimbrone, M.A.J., S.B. Leapman, R.S. Cotran, and J. Folkman. 1972. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136: 261-276.
21. Goldman, C.K., R.L. Kendall, G. Cabrera, L. Soroceanu, Y. Heike, G.Y. Gillespie, G.P. Siegal, X. Mao, A.J. Bett, W.R. Huckle et al. 1998. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. 95: 8795-8800.
22. Graeber, T.G., C. Osmanian, T. Jacks, D.E. Housman, C.J. Koch, S.W. Lowe, and A.J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91.
23. Guillemin, K., and M.A. Krasnow. 1997. The hypoxic response: Huffing and HIFing. Cell 89: 9-12.
24. Hanahan, D. and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
25. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 299-303.
26. Hershko, A. and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem 67: 425-479.
27. Holmgren, L., M.S. O'Reilly, and J. Folkman. 1995. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1: 149-153.
28. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25-27.
29. Huang, L.E., J. Gu, M. Schau, and H.F. Bunn. 1998. Regulation of hypoxia-inducible factor 1α is mediated by an oxygen-dependent domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. 95: 7987-7992.
30. 2 homeostasis by hypoxia inducible factor 1α. Genes & Dev. 12: 149-162.
31. Jiang, B.-H., E. Rue, G.L. Wang, R. Roe, and G.L. Semenza. 1996. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271: 17771-17778.
32. Jiang, B.-H., F. Agani, A. Passaniti, and G.L. Semenza. 1997. V-SRC induces expression of hypoxia-inducible factorl (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res. 57: 5328-5335.
33. Kallio, P.J., W.J. Wilson, S. O'Brien, Y. Makino, and L. Poellinger. 1999. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274: 6519-6525.
34. Kim, K.J., B. Li, J. Winer, M. Armanini, N. Gillett, H.S. Phillips, and N. Ferrara. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
35. Kotch, L.E., N.V. Iyer, E. Laughner, and G.L. Semenza. 1999. Defective vascularization of HIF-1α-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev. Biol. 209: 254-267.
36. Kubbutat, H.M.G., S.N. Jones, and K.H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299-303.
37. Kubbutat, M.H.G., R.L. Ludwig, A.J. Levine, and K.H. Vousden. 1999. Analysis of the degradation function of Mdm2. Cell Growth & Diff. 10: 87-92.
38. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
39. Lin, J., J. Chen, B. Elenbaas, and A.J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes & Dev. 8: 1235-1246.
40. Lowe, S.W. 1995. Cancer therapy and p53. Curr. Opin. Oncol. 7: 547-553.
41. Marston, N.J., J.R. Jenkins, and K.H. Vousden. 1995. Oligomerisation of full-length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10: 1709-1715.
42. Maxwell, P.H., G.U. Dachs, J.M. Gleadle, L.G. Nicholls, A.L. Harris, I.J. Stratford, O. Hankinson, C.W. Pugh, and P.J. Ratcliffe. 1997. Hypoxia-inducible factor 1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. 94: 8104-8109.
43. Maxwell, P.H., M.S. Wiesener, G.W. Chang, S.C. Clifford, E.C. Vaux, M.E. Cockman, C.C. Wykoff, C.W. Pugh, E.R. Maher, and P.J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
44. Mazure, N.M., E.Y. Chen, K.R. Laderoute, and A.J. Giaccia. 1997. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/ Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90: 3322-3331.
45. Millauer, B., L.K. Shawver, K.H. Plate, W. Risau, and A. Ullrich. 1994. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579.
46. Millauer, B., M.P. Longhi, K.H. Plate, L.K. Shawver, W. Risau, A. Ullrich, and L.M. Strawn. 1996. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56: 1615-1620.
47. Momand, J., G.P. Zambetti, D.L. George, and A.J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
48. Mukhopadhyay, D., L. Tsiokas, and V.P. Sukhatme. 1995. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55: 6161-6165.
49. Musti, A.M., M. Treier, and D. Bohmann. 1997. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275: 400-402.
50. O'Reilly, M.S., L. Holmgren, C. Chen, and J. Folkman. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2: 689-692.
51. Parangi, S., M.S. O'Reilly, G. Christofori, I. Holmgren, J. Grosfeld, J. Folkman, and D. Hanahan. 1996. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. 93: 2002-2007.
52. Plate, K.H., G. Breier, H.A. Weich, and W. Risau. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848.
53. Ravi, R., B. Mookerjee, Y.V. Hensbergen, G.C. Bedi, A. Giordano, W.S. El-Deiry, E.J. Fuchs, and A. Bedi. 1998. p53-mediated repression of nuclear factor κ-B RelA via the transcriptional integrator p 300. Cancer Res. 58: 4531-4536.
54. Risau, W. and I. Flamme. 1995. Vasculogenesis. Annu. Rev. Cell Dev. Biol. 11: 73-91.
55. Ryan, H.E., J. Lo, and R.S. Johnson. 1998. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17: 3005-3015.
56. Salceda, S. and J. Caro. 1997. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. J. Biol Chem. 272: 22642-22647.
57. Scheffner, M., B.A. Werness, J.M. Huibregtse, A.J. Levine, and P.M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
58. Scheffner, M., U. Nuber, and J.M. Huibregtse. 1995. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373: 81-83.
59. Semenza, G.L. 1999. Regulation of mammalian oxygen homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15: 551-578.
60. Semenza, G.L. and G.L. Wang. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12: 5447-5454.
61. Shweiki, D., A. Itin, D. Soffer, and E. Keshet. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845.
62. Van Meir, E.G., P.J. Polverini, V.R. Chazin, H.-J. Su Huang, N. de Tribolet, and W.K. Cavenee. 1994. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nature Genet. 8: 171-176.
63. Wang, G.L. and G.L. Semenza. 1993. Characterization of hypoxia-inducible factor-1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 268: 21513-21518.
64. Wang, G.L., B.-H. Jiang, E.A. Rue, and G.L. Semenza. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. 92: 5510-5514.
65. Warren, R.S., H. Yuan, M.R. Matli, N.A. Gillett, and N. Ferrara. 1995. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95: 1789-1797.
66. Wu, X.W., J.H. Bayle, D. Olson, and A.J. Levine. 1993. The p53 mdm-2 autoregulatory feedback loop. Genes & Dev. 7: 1126-1132.
67. Zhong H., A.M. DeMarzo, E. Laughner, M. Lim, A. Hilton, D. Zagzag, P. Buechler, W.B. Isaacs, G.L. Semenza, and J.W. Simons. 1999. Overexpression of hypoxia-inducible factor la in common human cancers and their metastases. Cancer Res. 59: 5830-5835.